OBJECTIVES: To evaluate excess mortality and risk factors for death during anti-tuberculosis treatment in Western Kenya. METHODS: We abstracted surveillance data and compared mortality rates during anti-tuberculosis treatment with all-cause mortality from a health and demographic surveillance population to obtain standardised mortality ratios (SMRs). Risk factors for excess mortality were obtained using a relative survival model, and for death during treatment using a proportional hazards regression model. RESULTS: The crude mortality rate during anti-tuberculosis treatment was 18.0 (95%CI 16.8-19.2) per 100 person-years. The age and sex SMR was 8.8 (95%CI 8.2-9.4). Excess mortality was greater in human immunodeficiency virus (HIV) positive TB patients (excess hazard ratio [eHR] 2.1, 95%CI 1.5-3.1), and lower in patients who were female or started treatment in a later year. Mortality was high in patients with unknown HIV status (HR 2.9, 95%CI 2.2-3.8) or, if HIV-positive, not on antiretroviral treatment (ART; HR 3.3, 95%CI 2.5-4.5) or not known to be on ART (HR 2.8, 95%CI 2.1-3.7). The attributable fraction of incomplete uptake of HIV testing and ART on mortality was 31% (95%CI 15-45) compared to HIV-positive patients on ART. CONCLUSION: Increasing the uptake of HIV testing and ART would further reduce mortality during anti-tuberculosis treatment by an estimated 31%.
OBJECTIVES: To evaluate excess mortality and risk factors for death during anti-tuberculosis treatment in Western Kenya. METHODS: We abstracted surveillance data and compared mortality rates during anti-tuberculosis treatment with all-cause mortality from a health and demographic surveillance population to obtain standardised mortality ratios (SMRs). Risk factors for excess mortality were obtained using a relative survival model, and for death during treatment using a proportional hazards regression model. RESULTS: The crude mortality rate during anti-tuberculosis treatment was 18.0 (95%CI 16.8-19.2) per 100 person-years. The age and sex SMR was 8.8 (95%CI 8.2-9.4). Excess mortality was greater in human immunodeficiency virus (HIV) positive TBpatients (excess hazard ratio [eHR] 2.1, 95%CI 1.5-3.1), and lower in patients who were female or started treatment in a later year. Mortality was high in patients with unknown HIV status (HR 2.9, 95%CI 2.2-3.8) or, if HIV-positive, not on antiretroviral treatment (ART; HR 3.3, 95%CI 2.5-4.5) or not known to be on ART (HR 2.8, 95%CI 2.1-3.7). The attributable fraction of incomplete uptake of HIV testing and ART on mortality was 31% (95%CI 15-45) compared to HIV-positive patients on ART. CONCLUSION: Increasing the uptake of HIV testing and ART would further reduce mortality during anti-tuberculosis treatment by an estimated 31%.
Authors: I Lucenko; V Riekstina; J Perevoscikovs; D Mozgis; M Khogali; J Gadoev; P de Colombani; A M V Kumar Journal: Public Health Action Date: 2014-10-21
Authors: Penelope A Phillips-Howard; Frank O Odhiambo; Mary Hamel; Kubaje Adazu; Marta Ackers; Anne M van Eijk; Vincent Orimba; Anja van't Hoog; Caryl Beynon; John Vulule; Mark A Bellis; Laurence Slutsker; Kevin deCock; Robert Breiman; Kayla F Laserson Journal: PLoS One Date: 2012-11-05 Impact factor: 3.240
Authors: Bruce J Kirenga; Jonathan Levin; Irene Ayakaka; William Worodria; Nancy Reilly; Francis Mumbowa; Helen Nabanjja; Grace Nyakoojo; Kevin Fennelly; Susan Nakubulwa; Moses Joloba; Alphonse Okwera; Kathleen D Eisenach; Ruth McNerney; Alison M Elliott; Roy D Mugerwa; Peter G Smith; Jerrold J Ellner; Edward C Jones-López Journal: PLoS One Date: 2014-03-07 Impact factor: 3.240
Authors: Penelope A Phillips-Howard; Kayla F Laserson; Nyaguara Amek; Caryl M Beynon; Sonia Y Angell; Sammy Khagayi; Peter Byass; Mary J Hamel; Anne M van Eijk; Emily Zielinski-Gutierrez; Laurence Slutsker; Kevin M De Cock; John Vulule; Frank O Odhiambo Journal: PLoS One Date: 2014-11-26 Impact factor: 3.240
Authors: Grace Lui; Rity Y K Wong; Florence Li; May K P Lee; Raymond W M Lai; Timothy C M Li; Joseph K M Kam; Nelson Lee Journal: PLoS One Date: 2014-03-18 Impact factor: 3.240
Authors: Courtney M Yuen; Herman O Weyenga; Andrea A Kim; Timothy Malika; Hellen Muttai; Abraham Katana; Lucy Nganga; Kevin P Cain; Kevin M De Cock Journal: PLoS One Date: 2014-06-17 Impact factor: 3.240